If formulary decisions are to be considered credible they must meet the standards of normal science. If they do not then they are best seen as pseudoscience. If clinical and modeled cost-effectiveness claims fail the standards of experimentation - evaluation and replication - then they are best regarded, not as normal science but as intelligent design. While this may seem an unreasonably harsh jusgment, it is the only conclusion one can come to when current standards for clinical and cost-effective value claims are considered.
Under the auspices of the Program in Social and Administrative Pharmacy, College of Pharmacy, University of Minnesota, proposed Guidelines for Formulary Evaluations have been proposed that meet the standards of credibility, evaluation and replication in clinical and cost-outcomes claims. Version 2.0 of the guideklines (published in December 2016) are detailed in the next section of this website.
IThese guidelines can be customized to meet the requirements of health systems. Maimon Research can advise on how this can be best achieved. At the same time Maimon Research can advise on establishing the software infrastructure to support the application of claims protocols to evaluate claims and provide feddback to physicians, patients and health system decision makers.